Evidence map›Paper›PMID 25706290›Full record

ArticlePloS one2015

Complementary amplicon-based genomic approaches for the study of fungal communities in humans.

Timothy Heisel, Heather Podgorski, Christopher M Staley, Dan Knights, Michael J Sadowsky, Cheryl A Gale

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Low-Abundant Microorganisms: The Human Microbiome's Dark Matter, a Scoping Review.Frontiers in cellular and infection microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Timothy HeiselDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, 55454, United States of America.
Heather PodgorskiDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, 55454, United States of America.
Christopher M StaleyBiotechnology Institute, University of Minnesota, St. Paul, MN, 55108, United States of America.
Dan KnightsBiotechnology Institute, University of Minnesota, St. Paul, MN, 55108, United States of America; Department of Computer Science and Engineering, University of Minnesota, Minneapolis, MN, 55455, United States of America.
Michael J SadowskyBiotechnology Institute, University of Minnesota, St. Paul, MN, 55108, United States of America; Department of Soil, Water, and Climate, University of Minnesota, St. Paul, MN, 55108, United States of America.
Cheryl A GaleDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, 55454, United States of America; Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, 55455, United States of America.
University of Minnesota · USBiotechnology Institute · US

Funding

Identification of Intestinal Bacteria Protective against C. Difficile ColitisR21AI091907 · NIAID · UNIVERSITY OF MINNESOTA · PI KHORUTS, ALEXANDER, SADOWSKY, MICHAEL JAY · 2011 to 2012
$415k
NIAID NIH HHS R21 AI091907NIAID NIH HHS R21AI091907
6 · The paper itself

Abstract

Recent studies highlight the importance of intestinal fungal microbiota in the development of human disease. Infants, in particular, are an important population in which to study intestinal microbiomes because microbial community structure and dynamics during this formative window of life have the potential to influence host immunity and metabolism. When compared to bacteria, much less is known about the early development of human fungal communities, owing partly to their lower abundance and the relative lack of established molecular and taxonomic tools for their study. Herein, we describe the development, validation, and use of complementary amplicon-based genomic strategies to characterize infant fungal communities and provide quantitative information about Candida, an important fungal genus with respect to intestinal colonization and human disease. Fungal communities were characterized from 11 infant fecal samples using primers that target the internal transcribed spacer (ITS) 2 locus, a region that provides taxonomic discrimination of medically relevant fungi. Each sample yielded an average of 27,553 fungal sequences and Candida albicans was the most abundant species identified by sequencing and quantitative PCR (qPCR). Low numbers of Candida krusei and Candida parapsilosis sequences were observed in several samples, but their presence was detected by species-specific qPCR in only one sample, highlighting a challenge inherent in the study of low-abundance organisms. Overall, the sequencing results revealed that infant fecal samples had fungal diversity comparable to that of bacterial communities in similar-aged infants, which correlated with the relative abundance of C. albicans. We conclude that targeted sequencing of fungal ITS2 amplicons in conjunction with qPCR analyses of specific fungi provides an informative picture of fungal community structure in the human intestinal tract. Our data suggests that the infant intestine harbors diverse fungal species and is consistent with prior culture-based analyses showing that the predominant fungus in the infant intestine is C. albicans.

Indexed as

GenomicsCandida albicansDNA, FungalFecesFungiHumansInfantPolymerase Chain ReactionDNA, Fungal

Identifiers

PMID25706290
PMCPMC4338280
OpenAlexW2008521575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.